Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbon nanoparticle-epirubicin targeted axillary lymph node chemotherapy in breast cancer
ChiCTR-TRC-13003419Phase 4Recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Aug 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of epirubicin in breast cancer (3 arms), sponsored by Southwest Hospital of Army Medical University. Primary endpoints: 1-year relapse/metastasis rate, 3-year relapse/metastasis rate and 4 more. Started Aug 2013; status: recruiting.
02
Drugs
epirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-TRC-13003419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003419.